Loading
Suzhou BlueHorse Therapeutics is a China-based cell therapy company that leads 2 cancer trials in OnCo, testing the tumour-infiltrating lymphocyte product LM103 in non-small-cell lung cancer and melanoma.
Suzhou BlueHorse Therapeutics is a Suzhou-based cell therapy developer. The ClinicalTrials.gov registry lists it as lead sponsor of phase 2 trials of LM103, a tumour-infiltrating lymphocyte (TIL) product, in non-small-cell lung cancer and melanoma. Its website could not be reached, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07444437 (phase 2, A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung C...) and NCT07310784 (phase 2, A Phase II Trial of LM103 in Advanced Melanoma). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Dacarbazine is an older chemotherapy infusion. It was the standard treatment for advanced melanoma for decades and is the D in the ABVD regimen that cures most Hodgkin lymphoma.
The only chemotherapy proven to extend life in glioblastoma, given during and after radiation. It works best when the tumour has switched off a repair gene called MGMT.
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.
Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.
Shares Dacarbazine, Temozolomide, Paclitaxel / nab-paclitaxel, Melanoma.
Shares Temozolomide, Melanoma.
Shares Temozolomide, Cisplatin.
Shares Temozolomide, Melanoma.
Shares Dacarbazine, Cisplatin, Carboplatin.
Shares Temozolomide, Carboplatin.
Shares Dacarbazine, Melanoma.
Shares Temozolomide, Carboplatin.